TY - JOUR

T1 - Methods of the synthesis of silicon-containing nanoparticles intended for nucleic acid delivery

AU - Levina, A. S.

AU - Repkova, M. N.

AU - Ismagilov, Z. R.

AU - Zarytova, V. F.

PY - 2018/9/7

Y1 - 2018/9/7

N2 - A promising new approach to the treatment of viral infections and genetic diseases associated with damaged or foreign nucleic acids in the body is gene therapy, i.e., the use of antisense oligonucleotides, ribozymes, deoxyribozymes, siRNA, plasmid DNA, etc. (therapeutic nucleic acids). Selective recognition of target nucleic acids by these compounds based on highly specific complementary interaction can minimize negative side effects, which occur with currently used low molecular weight drugs. To apply a new generation of therapeutic agents in medical practice, it is necessary to solve the problem of their delivery into cells. Silicon-containing nanoparticles are considered as promising carriers for this purpose due to their biocompatibility, low toxicity, ability to biodegradation and excretion from the body, as well as the simplicity of the synthesis and modification. Silicon-containing nanoparticles are divided into two broad categories: solid (nonporous) and mesoporous silicon nanoparticles (MSN). This review gives a brief overview of the creation of mesoporous, multilayer, and other silicon-based nanoparticles. The publications concerning solid silicon-organic nanoparticles capable of binding and delivering nucleic acids into cells are discussed in more detail with emphasis on methods for their synthesis. The review covers publications over the past 15 years, which describe the classical Stöber method, the microemulsion method, modification of commercial silica nanoparticles, and other strategies.

AB - A promising new approach to the treatment of viral infections and genetic diseases associated with damaged or foreign nucleic acids in the body is gene therapy, i.e., the use of antisense oligonucleotides, ribozymes, deoxyribozymes, siRNA, plasmid DNA, etc. (therapeutic nucleic acids). Selective recognition of target nucleic acids by these compounds based on highly specific complementary interaction can minimize negative side effects, which occur with currently used low molecular weight drugs. To apply a new generation of therapeutic agents in medical practice, it is necessary to solve the problem of their delivery into cells. Silicon-containing nanoparticles are considered as promising carriers for this purpose due to their biocompatibility, low toxicity, ability to biodegradation and excretion from the body, as well as the simplicity of the synthesis and modification. Silicon-containing nanoparticles are divided into two broad categories: solid (nonporous) and mesoporous silicon nanoparticles (MSN). This review gives a brief overview of the creation of mesoporous, multilayer, and other silicon-based nanoparticles. The publications concerning solid silicon-organic nanoparticles capable of binding and delivering nucleic acids into cells are discussed in more detail with emphasis on methods for their synthesis. The review covers publications over the past 15 years, which describe the classical Stöber method, the microemulsion method, modification of commercial silica nanoparticles, and other strategies.

KW - Delivery in cells

KW - Nucleic acids

KW - Silicon-containing nanoparticles

KW - Synthesis

KW - synthesis

KW - SURFACE FUNCTIONALIZATION

KW - ONE-POT SYNTHESIS

KW - DRUG-DELIVERY

KW - IN-VIVO BIODISTRIBUTION

KW - nucleic acids

KW - silicon-containing nanoparticles

KW - delivery in cells

KW - BLOOD-CELL PRODUCTION

KW - GM-CSF GENE

KW - INTRACELLULAR DELIVERY

KW - MESOPOROUS SILICA

KW - ANTISENSE OLIGONUCLEOTIDES

KW - BIOLOGICAL APPLICATIONS

UR - http://www.scopus.com/inward/record.url?scp=85055195107&partnerID=8YFLogxK

U2 - 10.18321/ectj720

DO - 10.18321/ectj720

M3 - Article

AN - SCOPUS:85055195107

VL - 20

SP - 177

EP - 194

JO - Eurasian Chemico-Technological Journal

JF - Eurasian Chemico-Technological Journal

SN - 1562-3920

IS - 3

ER -